tyrphostin A23

inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source

Also Known As:

(3,4-dihydroxybenzylidene)malononitrile; (3,4-dihydroxyphenyl)methylene propanedinitrile; 3,4-dihydroxybenzylidenemalononitrile; RG 50810; RG-50810; tyrphostin 23; tyrphostin A1; tyrphostin AG18; tyrphostin RG50810

Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Blumrich, Eva-Maria: 1 article (01/2017)
2.	Dringen, Ralf: 1 article (01/2017)
3.	Hohnholt, Michaela C: 1 article (01/2017)
4.	Waagepetersen, Helle S: 1 article (01/2017)
5.	Horie, Shigeo: 1 article (05/2008)
6.	Ide, Hisamitsu: 1 article (05/2008)
7.	Kamiyama, Yutaka: 1 article (05/2008)
8.	Muto, Satoru: 1 article (05/2008)
9.	Nakagawa, Takashi: 1 article (05/2008)
10.	Terado, Yuichi: 1 article (05/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "Tyrphostin 23 (T23) is a well-known inhibitor of protein tyrosine kinases and has been considered as potential anti-cancer drug. " 07/25/2023 - "Molecular docking was employed to investigate the binding mode and interaction sites of the derivatives (1-6) with three human cancer targets (HER2, EGFR, and human FPPS), and the protein-ligand interactions of these derivatives were compared to those reference standards Tyrphostin 1 (AG9) and Tyrphostin 23 (A23). " 11/10/1995 - "We recently reported that tyrphostin 23 (3,4-dihydroxybenzylidene malononitrile) is unstable in solution and that some of the degradation products are better inhibitors of the tyrosine kinase activity of Src and the EGF-receptor kinase than the parent compound itself (Ramdas et al., Cancer Res. 54, 867-868, 1994). "
2.	Lung Injury 04/15/2005 - "Here we report that systemic inhibition of these kinases using specific small molecule inhibitors (PP2, SU6656, tyrphostin A1) significantly attenuated LPS-induced lung injury, as determined by histologic and capillary permeability assays. "
3.	Prostatic Neoplasms (Prostate Cancer) 05/02/2008 - "We used a small interfering RNA targeting Tyk2 and an inhibitor of Tyk2, tyrphostin A1, to suppress the expression and signaling of Tyk2 in prostate cancer cells. "
4.	Hypercapnia 01/01/2003 - "After exposure to H/I, PAD in response to hypercapnia was impaired, but pretreatment with either genistein, tyrphostin A23, U-0126, or PD-98059 partially protected such impairment (17 +/- 1% vs. 4 +/- 1% vs. 9 +/- 1% for sham control, H/I, and H/I + genistein pretreatment, respectively). "
5.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/01/2001 - "Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage, Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice."

Related Drugs and Biologics

1.	Protein-Tyrosine Kinases (Tyrosine Kinase)
2.	Phosphotransferases (Kinase)
3.	ErbB Receptors (EGF Receptor)
4.	Small Interfering RNA (siRNA)
5.	Tyrphostins
6.	Genistein
7.	Interleukin-12 (IL 12)
8.	Verapamil (Calan)
9.	Tyrosine (L-Tyrosine)
10.	Solutions